
- /
- Supported exchanges
- / US
- / WGSWW.NASDAQ
GeneDx Holdings Corp. (WGSWW NASDAQ) stock market data APIs
GeneDx Holdings Corp. Financial Data Overview
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GeneDx Holdings Corp. data using free add-ons & libraries
Get GeneDx Holdings Corp. Fundamental Data
GeneDx Holdings Corp. Fundamental data includes:
- Net Revenue: 362 M
- EBITDA: 29 595 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GeneDx Holdings Corp. News

Four Reasons To Watch This 'Breakthrough' Stock — Including 954% Expected Growth
Earning an FDA Breakthrough Device Designation, GeneDx stock targets a breakout ahead of earnings — and expectations of 954% growth. Continue Reading View Comments


GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
Data from more than 22,000 newborns reinforce GeneDx’s role spearheading the adoption of genomic newborn screening (gNBS) from research to clinical practice GAITHERSBURG, Md., October 22, 2025--(BU...

Apple upgraded, Rivian downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GAITHERSBURG, Md., October ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.